U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07391839) titled 'MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.' on Dec. 17, 2025.
Brief Summary: The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma. Other purposes of this study include assessment of the effect of treatment on overall survival, the length of time it takes for the disease to worsen, if and how the treatment affects the patient's quality of life, and if and how the cancer responds to the treatment.
Study Start Date: Aug. 04, 2025
Study Type: INTERVENTIONAL
Condition...